

Diagnosis of Pheochromocytoma

NCT00004847

| | |
|-------------------|---|
| Status | RECRUITING |
| Phase | Phase 1 |
| Sponsor | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
| Enrollment | 3,000 participants |

Key Eligibility Criteria

Inclusion (16)

- Patients are eligible for inclusion in this study if they are adults or children of age 3 years old and up with known, sporadic or familial PHEO/PGL, on the basis of one or more of the following:
- High levels of blood or urinary catecholamines, metanephrines, methoxytyramine or chromogranin A.
- Highly suspected presence of PHEO/PGL based on imaging studies, even with normal biochemistry.
- Personal or family history of PHEO/PGL or genetic pathogenic variants known to predispose individuals to develop PHEO/PGL.
- Signed informed consent is required. The informed consent may be signed by the patient, parent/guardian in pediatric patients or legally authorized representative (LAR) in adults who lack decision making capacity to consent to research participation.

... and 11 more (see full listing online)

Exclusion (14)

- Potential patients will be excluded on the basis of one or more of the following:
- Pregnant or breastfeeding women
- Severe cardiac dysfunction
- Currently on dialysis
- A pregnancy test is performed in women of childbearing age (up to age 55) as a screening after consenting. If a patient is found to have a positive pregnancy test, her participation in this protocol will be terminated. The patient can enroll or re-enroll in the protocol when she is no longer pregnant or breastfeeding.

... and 9 more (see full listing online)

Locations (1 total)

National Institutes of Health Clinical Center, Bethesda, Maryland, United States